What changed from existing technology?
This study tested a powder containing a type of good bacteria that can be inhaled to reduce lung inflammation and stop the growth of a harmful bacteria called S. aureus in people with a lung condition called bronchiectasis.
This study is the first to explore the use of Lpb. plantarum in inhalation powders for treating bronchiectasis, focusing on both anti-inflammatory and antimicrobial effects.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
OpenAlex author affiliations: Roquette Frères (France), Qualicaps (Japan)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Validation stage
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The inhalation powders containing Lpb. plantarum may offer a new approach for managing inflammation and bacterial growth in non-CF bronchiectasis, though further clinical studies are needed.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchLpb. plantarum inhalation powders for the reduction of lung inflammation and S. aureus growth control in non-CF bronchiectasisExpert Opinion on Drug Delivery · Published 2026-08-30 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.